I'll warn you now that if you a fan of or shareholder in Organovo Holdings Inc. (NYSEMKT:ONVO), you're not going to like what you're about to hear. Sorry, but I have to call 'em like I see 'em. And what I see with ONVO is an overbought stock ripe for a big tumble.
First and foremost, if the ticker rings a bell, it may be because yours truly suggested ONVO was overbought and ready to pull back a couple of days ago. So much for my timing. Today, however, a couple of bearish clues have been tacked on, and I don't think Organovo Holdings is going to escape it unscathed.
The biggest clue is just the depth/veracity of today's rollover. The momentum leading up to today has been super-strong, but may have reached 'overheated' levels with the bullish opening gap left behind with today's move. Sure enough, the would-be profit-takers immediately decided enough is enough, and have carried Organovo Holdings shares to their first daily loss in six days.
5 Best Information Technology Stocks To Buy For 2015: Doral Financial Corporation (DRL)
Doral Financial Corporation operates as a bank holding company for Doral Bank that provides retail banking services to general public and institutions. It operates through four segments: Puerto Rico, the United States, Liquidating Operations, and Treasury. The company accepts deposits; obtains borrowings; originates and invests in loans, including residential real estate mortgage loans; invests in mortgage-backed securities and other investment securities; and offers traditional banking services. It also offers commercial and construction loan products; and purchases assigned interests in senior credit facilities from the syndicated leverage loan market in the United States. In addition, the company provides consumer loans, such as consumer credit, personal loans, loans on savings deposits, and other consumer loans. Further, it offers commercial real estate loans; commercial loans, including lines of credit and term facilities, and working capital for specific purposes, su ch as to finance the purchase of assets, equipment, or inventory; and construction lending products, as well as industrial and land loans. Additionally, the company originates, purchases, and sells mortgage loans; and offers property, casualty, life, and title insurance products primarily to its mortgage loan customers. It operates a network of 26 branches in Puerto Rico; 3 branches in the metropolitan area of New York; and 5 branches in the northwest area of Florida. Doral Financial Corporation was founded in 1972 and is based San Juan, Puerto Rico.
Advisors' Opinion:- [By Jayson Derrick]
An attorney at Doral (NYSE: DRL) stated that the company has “not left negotiations” with Puerto Rico's Treasury. Shares lost 2.86 percent, closing at $8.15.
- [By John Udovich]
For investors looking for exposure to the US commonwealth of Puerto Rico, banking stocks Doral Financial Corp (NYSE: DRL), First Bancorp (NYSE: FBP), OFG Bancorp (NYSE: OFG) and Popular Inc (NASDAQ: BPOP) offer the best bet as these Puerto Rico stocks trade on major US exchanges rather than the OTC. However, it should be mentioned that there has been a slowdown in Puerto Rico�� economy which has also shrunk in five of the past seven fiscal years. Then last�February, Puerto Rico�� debt was cut to speculative grade by the three largest credit-rating companies while�Governor Alejandro Garcia Padilla has proposed a series of budget cuts to help tackle the island�� mounting debt load -including the freezing public workers��salaries and the closing about 100 schools.
Top Diversified Bank Stocks To Buy Right Now: Rediff.com India Limited(REDF)
Rediff.com India Limited provides online Internet based services in India and to the global Indian community. The company's Websites consist of channels relevant to Indian interests, such as cricket, astrology, matchmaker, and movies; content on various matters, which include news and finance; search facilities; and a range of community features consisting of e-mail, chat, messenger, photo/video sharing capabilities, e-commerce, blogs, broadband wireless content, and mobile value-added services to mobile phone subscribers in India, as well as online advertising and online shopping services. It also publishes two weekly newspapers, ?India Abroad? and ?India in New York? for the Indian-American community based in the United States and Canada. The company?s target client base for advertising and sponsorships include global companies doing business in India, domestic corporations, and small and medium enterprises. As of March 31, 2010, it had 89.5 million online registered use rs. The company was formerly known as Rediff Communication Private Limited and changed its name to Rediff.com India Limited in February 2000. Rediff.com India Limited was founded in 1996 and is headquartered in Mumbai, India.
Advisors' Opinion:- [By Monica Gerson]
Rediff.com India (NASDAQ: REDF) is estimated to report its Q1 earnings.
American Apparel (NYSE: APP) is projected to post a Q2 loss at $0.06 per share on revenue of $162.50 million.
Top Diversified Bank Stocks To Buy Right Now: Neurocrine Biosciences Inc.(NBIX)
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; GnRH Antagonists for men?s and women?s health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott International Luxembourg S.�r.l. to develop and commercialize elagolix and GnRH antagonists for women?s and men?s health indications; and Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Ben Levisohn]
Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.
- [By Roberto Pedone]
Another stock that's starting to trend within range of triggering a major breakout trade is Neurocrine Biosciences (NBIX), which discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. This stock has been a hot name with bulls so far in 2013, with shares up 57%.
If you look at the chart for Neurocrine Biosciences, you'll notice that this stock recently gapped down sharply from $16.74 to below $11.50 a share with heavy downside volume flows. Following that gap down, shares of NBIX went on to continue its trend lower and the stock hit a new low of $10.42 a share. Shares of NBIX have started to rebound off that $10.42 low and it's now moving within range of triggering a major breakout trade.
Traders should now look for long-biased trades in NBIX if it manages to break out above some near-term overhead resistance levels at its 200-day moving average of $11.92 a share and above its gap down day high of $12.17 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 894,145 shares. If that breakout triggers soon, then NBIX will set up to re-fill some of its previous gap down zone from September that started at $16.74 a share. Some possible upside targets for NBIX if it gets into that gap with volume are $14 to $15 a share.
Traders can look to buy NBIX off any weakness to anticipate that breakout and simply use a stop that sits right below support at $11 a share, or below that recent low of $10.42 a share. One can also buy NBIX off strength once it takes out that breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By John Udovich]
Yesterday, small cap biopharmaceutical stock Neurocrine Biosciences, Inc (NASDAQ: NBIX) surged 89.69% after announcing positive results for its VMAT2 inhibitor NBI-98854 as a treatment for tardive dyskinesia, meaning investors late to the party or those already in should take a closer look at the stock along with its performance verses that of biotech ETFs like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
Top Diversified Bank Stocks To Buy Right Now: Income Opportunity Realty Trust (IOT)
Income Opportunity Realty Investors, Inc. operates in the real estate sector in the United States. As of March 31, 2009, it had 3 commercial properties consisting of 1 office building, 1 industrial warehouse, and 1 shopping center; and 211 acres of unimproved land situated in Farmers Branch, Texas. The company also involves in financing real estate and real estate related activities through investments in mortgage loans. Income Opportunity Realty Investors was founded in 1984 and is based in Dallas, Texas. As of July 17, 2009, Income Opportunity Realty Investors, Inc. operates as a subsidiary of Transcontinental Realty Investors Inc.
Advisors' Opinion:- [By Riddhi Kharkia]
Now, coming to talk about the third quarter, the two most important aspects that will impact Intel�� earnings will be PC demand and company�� position in the Internet of Things (IoT) market. We will discuss each of these in order so that the readers can have a better understanding of the things that will impact the chipmaker�� earnings. To start with, the PC group is at the heart of Intel�� operations and even though PC demand might be volatile, the PC group forms approximately half of the giant�� revenue.
- [By mitu77]
The new buzz of the market is Internet of Everything(IoE) and the associated gadgets as Internet of Things(IoT). Total number of devices that are inter-connected over internet surpasses the global population of the planet. In the very near future, pretty much everything you can imagine will wake up. We are leading the next step in the evolution of the Internet and helping change the way we work, live, play and learn. 25 billion devices will be connected by next year, and that number will grow to 50 billion by 2020. The greater part of this new information that the IoE produces will change the occupation scene for eternity.
No comments:
Post a Comment